CUVITRU is indicated as replacement therapy for primary humoral immunodeficiency (PI) in adult and pediatric patients ≥2 years. CUVITRU is for subcutaneous use only.
CUVITRU is indicated as replacement therapy for primary humoral immunodeficiency (PI) in adult and pediatric patients ≥2 years. CUVITRU is for subcutaneous use only.
Use the infusion calculator to explore CUVITRU [Immune Globulin Subcutaneous (Human)] 20% Solution administration parameter combinations for your patients based on needlesticks and frequency of infusions, and help your patients achieve CUVITRU’s maximum infusion rate by selecting the proper supplies.
*CUVITRU: Maximum volume per site is 60 mL/site as tolerated (except for the first 2 infusions for patients <40 kg). Maximum infusion rate is 60 mL/hr/site as tolerated (after first 2 infusions). Up to 4 sites simultaneously may be used.1
Calculations are based on a 28-day month and assumes the maximum volume per site and maximum infusion rate after the first two infusions.
All values are rounded up to the nearest whole number. This tool does not provide treatment recommendations or infusion parameters.
*CUVITRU: Maximum volume per site is 60 mL/site as tolerated (except for the first 2 infusions for patients <40 kg). Maximum infusion rate is 60 mL/hr/site as tolerated (after first 2 infusions). Up to 4 sites simultaneously may be used.1
Calculations are based on a 28-day month and assumes the maximum volume per site and maximum infusion rate after the first two infusions.
All values are rounded up to the nearest whole number. This tool does not provide treatment recommendations or infusion parameters.
*CUVITRU: Maximum volume per site is 60 mL/site as tolerated (except for the first 2 infusions for patients <40 kg). Maximum infusion rate is 60 mL/hr/site as tolerated (after first 2 infusions). Up to 4 sites simultaneously may be used.1
Calculations are based on a 28-day month and assumes the maximum volume per site and maximum infusion rate after the first two infusions.
All values are rounded up to the nearest whole number. This tool does not provide treatment recommendations or infusion parameters.
The following information is intended to assist HCPs in selection of appropriate equipment in order to achieve the maximum infusion rate of 60 mL/h/site with CUVITRU. Takeda does not prefer, recommend, or attest to using any specific infusion pump or other ancillary devices.
Follow each infusion pump’s manufacturer guidelines before use and administration.
RMS Freedom
Infusion
System2,3
EMED SCiG
Infusion
System4,5
HIgH-Flo Subcutaneous
Safety
Needle Sets™
Soft-Glide™
Needle Sets
There are known risk factors to consider with Cuvitru. Review the full safety information, including contraindications and specific warnings and precautions to take when monitoring patients with Cuvitru.
See Safety InformationFor more information, contact a Takeda representative.
Contact a Rep